/Healthcare%20researchers%20working%20in%20medical%20lab%20by%20chokniti%20via%20Adobe%20Stock.jpeg)
Washington, the District Of Columbia-based Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services. The company is valued at $151.9 billion by market cap.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and DHR definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the diagnostics & research industry. DHR’s competitive strengths come from its portfolio of high-margin, mission-critical tools in biotech, diagnostics, and life sciences. Strong positions in regulated, R&D-heavy markets give it pricing power and resilience, even in downturns.
Despite its notable strength, DHR shares slipped 11% from their 52-week high of $242.80, achieved on Jan. 22. Over the past three months, DHR stock has gained 19.6%, outperforming the Nasdaq Composite’s ($NASX) 1.9% dip during the same time frame.
Shares of DHR fell 5.6% on a YTD basis but climbed 5.3% over the past 52 weeks, underperforming NASX’s YTD gains of 13.6% and 21.6% returns over the last year.
To confirm the bullish trend, DHR has been trading above its 50-day moving average since early June, with some fluctuations. It is trading above its 200-day moving average since early August, with slight fluctuations.
DHR lagged mainly because of a slowdown in respiratory testing, while sentiment took an additional hit from softer-than-anticipated biotech sales more than $100 million in bioprocessing revenue slipped into next year due to timing of shipments, despite mid-teens growth in orders.
On Jul. 21, DHR shares tumbled 11% after reporting its Q2 results. Its adjusted EPS of $1.94 beat Wall Street expectations of $1.84. The company’s revenue was $6.3 billion, surpassing Wall Street forecasts of $6.1 billion. DHR expects full-year adjusted EPS in the range of $8.45 to $8.60.
In the competitive arena of diagnostics & research, Revvity, Inc. (RVTY) has taken the lead over DHR, showing resilience with a 33.1% uptick on a YTD basis and 44.4% gains over the past 52 weeks.
Wall Street analysts are bullish on DHR’s prospects. The stock has a consensus “Strong Buy” rating from the 24 analysts covering it, and the mean price target of $223.09 suggests a potential upside of 3.2% from current price levels.
